The latter is likely the case, given that GBM slices treated with FAS inhibitor showed a positive enrichment for the gene signature of astrocytes treated with FAS inhibitor, and negative enrichment for tissue state B. These finding are clinically relevant, given FASN is a promising target against glioblastoma43, and highlight how the tissue-state approach can provide insights into the effects of targeted therapies on the GBM microenvironment. This evidence concerns the gene FAS and glioblastoma.